Skip to main content
. 2022 Jul 22;10:947375. doi: 10.3389/fpubh.2022.947375

Figure 2.

Figure 2

Acceptability curves for the choice of nivolumab plus ipilimumab vs. chemotherapy at different WTP thresholds.